膜联蛋白 1-核因子-κB-微小 RNA-26a 调控通路在非小细胞肺癌转移中的作用。
Annexin 1-nuclear factor-κB-microRNA-26a regulatory pathway in the metastasis of non-small cell lung cancer.
机构信息
Key Laboratory of Oral Medicine, Guangzhou Institute of Oral Disease, Affiliated Stomatology Hospital of Guangzhou Medical University, Guangzhou, China.
Department of Biomedical Engineering, School of Basic Medical Sciences, Guangzhou Medical University, Xinzao, China.
出版信息
Thorac Cancer. 2019 Apr;10(4):665-675. doi: 10.1111/1759-7714.12982. Epub 2019 Feb 12.
BACKGROUND
Annexin 1 (ANXA1) expression is associated with the malignant tumor phenotype, making it an attractive therapeutic target. However, little is known about the regulation of ANXA1 in non-small cell lung cancer (NSCLC).
METHODS
We investigated the biological roles of ANXA1 in tumor growth, migration, and invasion, and explored the possibility of ANXA1 as a potential therapeutic target for the treatment of NSCLC.
RESULTS
Our findings revealed that ANXA1 enhanced nuclear factor (NF)-κB activation in NSCLC cells by interaction with inhibitor of NF-κB kinase complex subunit, IKKγ. We also found that NF-κB could negatively regulate microRNA (miR)-26a, and miR-26a was regulated through the ANXA1-NF-κB regulatory pathway. NF-κB activation negatively regulated by miR-26a was confirmed in NSCLC.
CONCLUSION
Together, these results provide evidence of the mechanisms of the ANXA1-NF-κB-miR-26a regulatory pathway in the invasion and migration in NSCLC.
背景
膜联蛋白 1（ANXA1）的表达与恶性肿瘤表型相关，使其成为有吸引力的治疗靶点。然而，关于非小细胞肺癌（NSCLC）中 ANXA1 的调节知之甚少。
方法
我们研究了 ANXA1 在肿瘤生长、迁移和侵袭中的生物学作用，并探讨了 ANXA1 作为治疗 NSCLC 的潜在治疗靶点的可能性。
结果
我们的研究结果表明，ANXA1 通过与 NF-κB 激酶复合物亚单位 IKKγ 的相互作用，增强了 NSCLC 细胞中的核因子（NF）-κB 激活。我们还发现 NF-κB 可以负调控 microRNA（miR）-26a，并且 miR-26a 通过 ANXA1-NF-κB 调节途径进行调节。NF-κB 的激活被 miR-26a 负调控，这在 NSCLC 中得到了证实。
结论
综上所述，这些结果为 ANXA1-NF-κB-miR-26a 调节途径在 NSCLC 侵袭和迁移中的机制提供了证据。
Zotero 插件